drugset
Drugs / autologous anti-BCMA chimeric antigen receptor T cells
last change Jun 2023 re-read 3 minutes ago

autologous anti-BCMA chimeric antigen receptor T cells

Cell therapy

Developed for
autoimmune thrombocytopenia
Investigated by
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · The First Affiliated Hospital of Soochow University

Trials 1

today NCT05315778 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05315778 Jan → Dec 2022 autoimmune thrombocytopenia The First Affiliated Hospital of Soochow University Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as autologous anti-BCMA chimeric antigen receptor T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT05315778 ↗
Modality Cell therapy “chimeric antigen receptor T cell therapy（BCMA CAR-T）” NCT05315778 ↗